Placebo-Controlled Trial Shows Reduced LDL Cholesterol Levels With Enlicitide

THURSDAY, Feb. 5, 2026-- The oral proprotein convertase subtilisin-kexin type 9 inhibitor enlicitide yields significantly lower low-density lipoprotein (LDL) cholesterol levels than placebo among participants who have a history of or have a risk...